These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 34986294)

  • 1. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.
    Eyre DW; Taylor D; Purver M; Chapman D; Fowler T; Pouwels KB; Walker AS; Peto TEA
    N Engl J Med; 2022 Feb; 386(8):744-756. PubMed ID: 34986294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
    Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
    Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
    Hall V; Foulkes S; Insalata F; Kirwan P; Saei A; Atti A; Wellington E; Khawam J; Munro K; Cole M; Tranquillini C; Taylor-Kerr A; Hettiarachchi N; Calbraith D; Sajedi N; Milligan I; Themistocleous Y; Corrigan D; Cromey L; Price L; Stewart S; de Lacy E; Norman C; Linley E; Otter AD; Semper A; Hewson J; D'Arcangelo S; Chand M; Brown CS; Brooks T; Islam J; Charlett A; Hopkins S;
    N Engl J Med; 2022 Mar; 386(13):1207-1220. PubMed ID: 35172051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.
    Shah SA; Robertson C; Rudan I; Murray JL; McCowan C; Grange Z; Buelo A; Sullivan C; Simpson CR; Ritchie LD; Sheikh A
    J Glob Health; 2022; 12():05008. PubMed ID: 35356660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Pouwels KB; Pritchard E; Matthews PC; Stoesser N; Eyre DW; Vihta KD; House T; Hay J; Bell JI; Newton JN; Farrar J; Crook D; Cook D; Rourke E; Studley R; Peto TEA; Diamond I; Walker AS
    Nat Med; 2021 Dec; 27(12):2127-2135. PubMed ID: 34650248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
    Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
    Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys.
    Chadeau-Hyam M; Wang H; Eales O; Haw D; Bodinier B; Whitaker M; Walters CE; Ainslie KEC; Atchison C; Fronterre C; Diggle PJ; Page AJ; Trotter AJ; Ashby D; Barclay W; Taylor G; Cooke G; Ward H; Darzi A; Riley S; Donnelly CA; Elliott P;
    Lancet Respir Med; 2022 Apr; 10(4):355-366. PubMed ID: 35085490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
    Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.
    Lumley SF; Rodger G; Constantinides B; Sanderson N; Chau KK; Street TL; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Stoesser NE; Matthews PC; Jeffery K; Eyre DW;
    Clin Infect Dis; 2022 Apr; 74(7):1208-1219. PubMed ID: 34216472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    Lopez Bernal J; Andrews N; Gower C; Gallagher E; Simmons R; Thelwall S; Stowe J; Tessier E; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown KE; Hopkins S; Chand M; Ramsay M
    N Engl J Med; 2021 Aug; 385(7):585-594. PubMed ID: 34289274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.